Figure 7.
Anti-CD19 improves survival in combination with 131I-labeled anti-MHCII in the BCL1 lymphoma model. BALB/c mice were inoculated with 105 cells by intravenous injection on day 0 and treated 10 days later with18.5 MBq 131I-labeled anti-MHCII plus unlabeled anti-Id, anti-CD38, or anti-CD19 mAb (500 μg of each intravenously). The above experiment is representative of 1 of 3 identical experiments and shows a significant survival improvement when the anti-Id or anti-CD19 was added to 18.5 MBq 131I anti-MHCII over 18.5 MBq 131I anti-MHCII alone (P < .01). No improvement was observed following addition of anti-CD38 mAb.
